Myovant Sciences Ltd (NYSE:MYOV)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - MYOV

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - MYOV

  • Market Cap$1.346bn
  • SymbolNYSE:MYOV
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINBMG637AM1024

Company Profile

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.Myovant Sciences Ltd is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its product candidate is relugolix.

Latest MYOV news

Currently there for this company. Visit our news hub for other news .